Healing and Improving Postnatal Nights Through Sleep (HIPNoS) (HIPNoS)
Healing and Improving Postnatal Nights Through Sleep (HIPNoS): A Randomized Controlled Trial Evaluating Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) in Postpartum Women With Insomnia and Depression.
Insomnia and depression are highly prevalent during postpartum, but effective treatment options are severely limited. Perinatal Understanding of Mindful Awareness (PUMAS) combines behavioral sleep strategies and mindfulness-based exercises to improve sleep and mood during pregnancy. Indeed, PUMAS has been shown to effectively treatment comorbid insomnia and depression in pregnancy in controlled and uncontrolled trials. The present randomized controlled trial (RCT) will evaluate the effectiveness of PUMAS in a sample of postpartum women with comorbid insomnia and depression who will be randomized to to telemedicine PUMAS or online sleep hygiene education (SHE; enhanced usual care). Patients will be treated for six weeks followed by assessment after treatment then follow-up assessment 3-months later. The investigators hypothesize that PUMAS patients, relative to SHE patients, will report superior acute treatment effects on insomnia and depression as well as more durable effects at 3-month follow-up.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Heba Research Operations Manager
- Telefoonnummer: (248) 344-7363
- E-mail: hafaneh1@HFHS.ORG
Studie Locaties
-
-
Michigan
-
Novi, Michigan, Verenigde Staten, 48377
- Henry Ford Medical Center - Columbus
-
Contact:
- Heba Research Operations Manager
- Telefoonnummer: (248) 344-7363
- E-mail: hafaneh1@HFHS.ORG
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial
- Participant must be able to engage in treatment (e.g., has internet access to attend telemedicine appointments or access online sleep hygiene materials).
- Aged 18 years or above.
- Postpartum 4-12 months at time of screening.
- Meets diagnostic criteria for DSM-5 insomnia disorder, acute (symptoms lasting ≥1 month).
- Clinically severe insomnia symptom severity (Insomnia Severity Index score ≥11).
- Clinically significant depression symptoms (Edinburg Postnatal Depression Scale score ≥10).
Exclusion Criteria:
- Sleep complaints primarily due to infant sleep problems as ascertained via clinical interview and/or describing the infant's sleep as a 'moderate' or 'serious' problem on the Brief Infant Sleep Questionnaire on the screening survey.
- Suicidal intent per the Columbus Suicide Severity Rating Scale (Suicidal ideation WITHOUT intent is NOT exclusionary).
- Current engagement in psychotherapy for insomnia disorder (current use of sleep aids [prescription, over-the-counter, or dietary supplements] is NOT exclusionary).
- Night or rotating shift work.
- Unreliable internet access that prevents a patient from being to engage with treatment and/or assessments.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
Participants assigned to receive the PUMAS intervention. |
A six-week psychotherapy protocol combining behavioral sleep strategies with mindfulness exercises with all components tailored to peripartum. PUMAS was initially developed for pregnancy and has been shown to be safe and effective for alleviating insomnia, depression, and cognitive arousal during pregnancy. Early evidence from real-world clinic data has shown that postpartum women with insomnia show the same treatment benefits as prenatal patients, thereby offering early support for effectiveness in pregnancy. PUMAS will be delivered via telemedicine video with a therapist. |
|
Ander: Sleep hygiene education (SHE)
Participants assigned to receive six weeks of educational materials as an enhanced usual-care control. |
Sleep hygiene education (SHE) on maternal sleep and infant sleep. A six-week psychoeducation that will be delivered via six weekly information sheets that will be delivered via email to patients. Perinatal patients report that SHE is the most recommended non-pharmacological treatment suggested for their insomnia. In the real world, SHE is typically delivered in a one-shot information sheet (e.g., after visit summary). However, to match for contact frequency, SHE information will be delivered to patients weekly across six weeks, which also allows for providing greater information on maternal and infant sleep, thereby representing enhanced usual care practice. Although SHE practices improve sleep quality, SHE is not considered an effective standalone treatment for insomnia, therefore making SHE an interventional control comparator. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Insomnia Severity Index (ISI)
Tijdsspanne: The investigators will examine change in ISI from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Insomnia Severity Index is a commonly used self-report measure of insomnia symptoms that has been validated in peripartum. ISI scores range from 0 to 28 with higher scores indicating greater insomnia severity. |
The investigators will examine change in ISI from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Edinburgh Postnatal Depression Scale (EPDS)
Tijdsspanne: The investigators will examine change in EPDS from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Edinburgh Postnatal Depression Scale (EDPS) is the most widely use depression measure in pregnancy and postpartum. EPDS scores range from 0 to 30 with higher scores indicating greater depression severity. |
The investigators will examine change in EPDS from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
|
Pre-Sleep Arousal Scale's cognitive factor (PSASC)
Tijdsspanne: The investigators will examine change in PSASC from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in peripartum. PSASC scores range 8 to 40 with higher scores indicating greater nocturnal cognitive arousal. |
The investigators will examine change in PSASC from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: David A. Kalmbach, PhD, Henry Ford Health
Publicaties en nuttige links
Algemene publicaties
- Kalmbach DA, Cheng P, Roth T, Swanson LM, Cuamatzi-Castelan A, Roth A, Drake CL. Examining Patient Feedback and the Role of Cognitive Arousal in Treatment Non-response to Digital Cognitive-behavioral Therapy for Insomnia during Pregnancy. Behav Sleep Med. 2022 Mar-Apr;20(2):143-163. doi: 10.1080/15402002.2021.1895793. Epub 2021 Mar 15.
- Swanson LM, Flynn H, Adams-Mundy JD, Armitage R, Arnedt JT. An open pilot of cognitive-behavioral therapy for insomnia in women with postpartum depression. Behav Sleep Med. 2013;11(4):297-307. doi: 10.1080/15402002.2012.683902. Epub 2012 Dec 6.
- Kalmbach DA, Cheng P, Drake CL. A pathogenic cycle between insomnia and cognitive arousal fuels perinatal depression: exploring the roles of nocturnal cognitive arousal and perinatal-focused rumination. Sleep. 2021 Jun 11;44(6):zsab028. doi: 10.1093/sleep/zsab028.
- Kalmbach DA, Cheng P, Ong JC, Ciesla JA, Kingsberg SA, Sangha R, Swanson LM, O'Brien LM, Roth T, Drake CL. Depression and suicidal ideation in pregnancy: exploring relationships with insomnia, short sleep, and nocturnal rumination. Sleep Med. 2020 Jan;65:62-73. doi: 10.1016/j.sleep.2019.07.010. Epub 2019 Jul 22.
- Kalmbach DA, Cheng P, Sangha R, O'Brien LM, Swanson LM, Palagini L, Bazan LF, Roth T, Drake CL. Insomnia, Short Sleep, And Snoring In Mid-To-Late Pregnancy: Disparities Related To Poverty, Race, And Obesity. Nat Sci Sleep. 2019 Nov 4;11:301-315. doi: 10.2147/NSS.S226291. eCollection 2019.
- Kalmbach DA, Ong JC, Cheng P, Reffi AN, Swanson LM, Hirata M, Seymour GM, Castelan-Cuamatzi AS, Jennings MB, Pitts DS, Roth A, Roth T, Drake CL. A randomized controlled trial of telemedicine CBTI and PUMAS for prenatal insomnia: Reducing nocturnal cognitive arousal is a treatment mechanism for alleviating insomnia and depression during pregnancy. Sleep Med. 2025 Sep;133:106570. doi: 10.1016/j.sleep.2025.106570. Epub 2025 May 12.
- Kalmbach DA, Cheng P, Reffi AN, Ong JC, Swanson LM, Fresco DM, Walch O, Seymour GM, Fellman-Couture C, Bayoneto AD, Roth T, Drake CL. Perinatal Understanding of Mindful Awareness for Sleep (PUMAS): A single-arm proof-of-concept clinical trial of a mindfulness-based intervention for DSM-5 insomnia disorder during pregnancy. Sleep Med. 2023 Aug;108:79-89. doi: 10.1016/j.sleep.2023.05.026. Epub 2023 Jun 10.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 19940
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .